Skip to main content

Mineralys Therapeutics, Inc.

corporate_fare Company Profile

Mineralys Therapeutics, Inc.

MLYS·NASDAQ·Life Sciences·CIK 0001933414

Mineralys Therapeutics, Inc. is a biopharmaceutical company that develops medicines for diseases caused by dysregulated aldosterone. The company's primary product candidate is lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor (ASI). Mineralys Therapeutics is developing lorundrostat to treat cardiorenal conditions affected by dysregulated aldosterone, including hypertension and related comorbidities such as chronic kidney disease (CKD) and obstructive sleep apnea (OSA). In the United States, approximately 120 million patients have sustained elevated blood pressure, or hypertension. Of these, approximately 60 million patients are treated, and over 30 million do not achieve their blood pressure goal, with approximately 20 million having systolic blood pressure levels greater than 140 mmHg. Patients with hypertension that persists despite taking two or more medications have 1.8 and 2.5 times greater mortality risk due to cardiovascular disease or stroke, respectively. Dysregulated aldosterone levels are a key factor in uncontrolled hypertension (uHTN) or resistant hypertension (rHTN) in approximately 30% of patients. Mineralys Therapeutics completed five clinical trials for lorundrostat, supporting its efficacy and safety profile and validating aldosterone as a therapeutic target in uHTN or rHTN. These trials include two pivotal, registrational trials: the Phase 3 Launch-HTN trial and the Phase 2 Advance-HTN trial, which demonstrated robust, durable, and clinically meaningful reductions in systolic blood pressure by lorundrostat. Lorundrostat was well tolerated in both trials with a favorable safety profile. The company submitted a New Drug Application (NDA) in December 2025 for lorundrostat for the treatment of hypertension in combination with other antihypertensive drugs. The FDA accepted the NDA submission and provided a Prescription Drug User Fee Act (PDUFA) target action date of December 22, 2026. Mineralys Therapeutics is also investigating lorundrostat's potential benefits in participants with hypertension and CKD and in participants with hypertension and OSA.

Mineralys Therapeutics, Inc. (NASDAQ:MLYS) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 23 items for MLYS at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-04, rated 7/10. Across its 20 most recent items scored 7 or higher, the top rating is 9/10, with 9 rated 8 or above. Recent SEC coverage for MLYS spans 10-Q, 8-K, 144, 424B5.

Recent high-impact activity:

  • Mineralys Q3 Loss Widens to $57.3M as Launch Spending Builds; $624.7M Cash
  • Mineralys Q3 Loss Widens to $57.3M as Lorundrostat Launch Build-Out Accelerates Ahead of Dec 22 PDUFA
  • Mineralys Closes Tanabe Termination, Owns Lorundrostat IP Outright but Keeps $265M Milestones
  • Lorundrostat Cuts BP 7.5 mmHg and Proteinuria in Phase 2 CKD Trial
  • Lorundrostat Cuts Albuminuria 52% in CKD as FDA Decision Nears

Financial Snapshot

Fiscal year ended December 31, 2025
Net Income
-$154.65M
Diluted EPS
-$2.29
Op. Cash Flow
-$142.42M
Free Cash Flow
-$142.43M
Operating Income
-$170.6M
Cash & Equivalents
$172.92M
Debt / Equity
0.00×
Shares Outstanding
81.54M sh
Source: 10-K · filed 2026-03-12 · accession 0001933414-26-000056

Short Interest & Short Volume

4.95 days to cover

FINRA reported short interest of 7,687,327 shares in MLYS as of the October 30, 2026 settlement, a 3.4% increase from the prior period — about 5.0 days to cover at its recent average daily volume. On November 20, 2026, 45.8% of MLYS volume reported to FINRA trade-reporting facilities was marked short.

Short interest (bi-monthly positions)7,687,327 shares as of October 30, 2026
Change vs prior period▲ 3.4%
Days to cover4.95 at avg daily volume of 1,551,996
Daily short volume (FINRA facilities)45.8% of 381,163 shares on November 20, 2026
5-day average short volume36.1%

Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.

Dilution Risk

Low risk

Filing-implied dilution signals for MLYS, detected from its recent SEC filings · based on capital-structure filings through 2026-06-03.

1 recent capital raise

Underwritten Common Stock Offering Priced · Significant Capital Raise

A filing-implied signal, not a realized share count. How Wiseek tracks dilution →

Browse all tickers starting with M →
$13.7 +0.29% today
52-week range · as of 2026-11-04 $13.7 – $47.65
Market cap
$1.21B
Volume
1.3M (0.7× avg)
3-mo avg 1.8M
Live data · 2026-11-22 04:06 UTC · Market closed

show_chartPrice Chart

Loading chart...

feed MLYS - Latest Insights

MLYS
Nov 04, 2026, 5:15 PM EST
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $16.82
Real-time Price: $13.70 info
Change: -$3.12 (-19%) info
Market Cap: $1.21B info
MLYS
Nov 04, 2026, 4:08 PM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $17.16
Real-time Price: $13.70 info
Change: -$3.46 (-20%) info
Market Cap: $1.21B info
MLYS
Oct 29, 2026, 4:08 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $21.24
Real-time Price: $13.70 info
Change: -$7.54 (-35%) info
Market Cap: $1.21B info
MLYS
Oct 28, 2026, 7:05 AM EDT
Source: Wiseek News
Importance Score:
7
Price at Filing: $21.30
Real-time Price: $13.70 info
Change: -$7.60 (-36%) info
Market Cap: $1.21B info
MLYS
Oct 22, 2026, 6:40 PM EDT
Source: Wiseek News
Importance Score:
7
Price at Filing: $21.47
Real-time Price: $13.70 info
Change: -$7.77 (-36%) info
Market Cap: $1.21B info
MLYS
Oct 09, 2026, 9:00 AM EDT
Source: Wiseek News
Importance Score:
7
Price at Filing: $22.35
Real-time Price: $13.70 info
Change: -$8.65 (-39%) info
Market Cap: $1.21B info
MLYS
Aug 17, 2026, 7:27 AM EDT
Source: Wiseek News
Importance Score:
7
Price at Filing: $26.09
Real-time Price: $13.70 info
Change: -$12.39 (-47%) info
Market Cap: $1.21B info
MLYS
Aug 11, 2026, 5:18 PM EDT
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $26.26
Real-time Price: $13.70 info
Change: -$12.56 (-48%) info
Market Cap: $1.21B info
MLYS
Aug 11, 2026, 4:08 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $26.15
Real-time Price: $13.70 info
Change: -$12.45 (-48%) info
Market Cap: $1.21B info
MLYS
Jun 30, 2026, 4:20 PM EDT
Filing Type: 144
Importance Score:
7
Price at Filing: $26.93
Real-time Price: $13.70 info
Change: -$13.23 (-49%) info
Market Cap: $1.21B info
MLYS
Jun 04, 2026, 3:14 AM EDT
Source: Wiseek News
Importance Score:
8
Price at Filing: $24.06
Real-time Price: $13.70 info
Change: -$10.36 (-43%) info
Market Cap: $1.21B info
MLYS
Jun 03, 2026, 4:07 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $25.06
Real-time Price: $13.70 info
Change: -$11.36 (-45%) info
Market Cap: $1.21B info
MLYS
Jun 03, 2026, 4:06 PM EDT
Filing Type: 424B5
Importance Score:
8
Price at Filing: $25.06
Real-time Price: $13.70 info
Change: -$11.36 (-45%) info
Market Cap: $1.21B info
MLYS
Jun 03, 2026, 10:31 AM EDT
Source: Dow Jones Newswires
Importance Score:
8
Price at Filing: $25.15
Real-time Price: $13.70 info
Change: -$11.45 (-46%) info
Market Cap: $1.21B info
MLYS
Jun 03, 2026, 6:05 AM EDT
Source: Dow Jones Newswires
Importance Score:
8
Price at Filing: $28.86
Real-time Price: $13.70 info
Change: -$15.16 (-53%) info
Market Cap: $1.21B info
MLYS
Jun 03, 2026, 6:02 AM EDT
Filing Type: 8-K
Importance Score:
9
Price at Filing: $29.00
Real-time Price: $13.70 info
Change: -$15.30 (-53%) info
Market Cap: $1.21B info
MLYS
May 18, 2026, 2:00 AM EDT
Source: Reuters
Importance Score:
8
Price at Filing: $27.15
Real-time Price: $13.70 info
Change: -$13.45 (-50%) info
Market Cap: $1.21B info
MLYS
May 06, 2026, 4:07 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $31.00
Real-time Price: $13.70 info
Change: -$17.30 (-56%) info
Market Cap: $1.21B info
MLYS
Mar 31, 2026, 4:15 PM EDT
Filing Type: 4
Importance Score:
7
Price at Filing: $28.75
Real-time Price: $13.70 info
Change: -$15.05 (-52%) info
Market Cap: $1.21B info
MLYS
Mar 12, 2026, 5:19 PM EDT
Filing Type: 10-K
Importance Score:
8
Price at Filing: $26.21
Real-time Price: $13.70 info
Change: -$12.51 (-48%) info
Market Cap: $1.21B info
Research tools: Filing Impact Index Dilution Tracker Split Calendar Open Datasets